Introduction: Breast cancer in men is less common than in women and treatment recommendations are often derived from clinical trials exclusively involving women. Data on efficacy of CDK 4/6 inhibitors, which are the mainstay of treatment for hormone receptor–positive/HER2-negative advanced breast cancer, are lacking in male patients. Case report: We present a clinical case of prolonged benefit from palbociclib in combination with letrozole and LHRH analogue in a man who had previously been treated with six lines of endocrine therapies and chemotherapy regimens but was still in excellent clinical condition. Conclusions: This clinical case demonstrates that male breast cancer stands out as an endocrine-sensitive disease, which could potentially benefit from CDK 4/6 inhibitors in combination with endocrine agents even in very heavily pretreated settings of disease, underscoring both the importance of an accurate selection of patients for later treatment lines, taking into account disease history and previous treatment responses, and the peculiarity of breast cancer in men, which deserves dedicated clinical trials to tailor future recommendations.

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report / E. Zattarin, F. Ligorio, F. Nichetti, G. Bianchi, G. Capri, F. de Braud. - In: TUMORI. - ISSN 0300-8916. - 107:6(2021 Dec), pp. NP15-NP19. [10.1177/0300891620976981]

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report

Zattarin E.;Ligorio F.;Nichetti F.;de Braud F.
2021-12

Abstract

Introduction: Breast cancer in men is less common than in women and treatment recommendations are often derived from clinical trials exclusively involving women. Data on efficacy of CDK 4/6 inhibitors, which are the mainstay of treatment for hormone receptor–positive/HER2-negative advanced breast cancer, are lacking in male patients. Case report: We present a clinical case of prolonged benefit from palbociclib in combination with letrozole and LHRH analogue in a man who had previously been treated with six lines of endocrine therapies and chemotherapy regimens but was still in excellent clinical condition. Conclusions: This clinical case demonstrates that male breast cancer stands out as an endocrine-sensitive disease, which could potentially benefit from CDK 4/6 inhibitors in combination with endocrine agents even in very heavily pretreated settings of disease, underscoring both the importance of an accurate selection of patients for later treatment lines, taking into account disease history and previous treatment responses, and the peculiarity of breast cancer in men, which deserves dedicated clinical trials to tailor future recommendations.
cyclin-dependent kinase 4/6 inhibitors; endocrine treatment; hormone receptor–positive breast cancer; Male breast cancer; palbociclib; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Humans; Letrozole; Male; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy;
Settore MED/06 - Oncologia Medica
9-dic-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
prolonged benefit.pdf

solo utenti autorizzati

Tipologia: Publisher's version/PDF
Dimensione 256.2 kB
Formato Adobe PDF
256.2 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/908364
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact